📊 GWLL Key Takeaways
Is Goldenwell Biotech, Inc.. (GWLL) a Good Investment?
GWLL exhibits severe financial distress with negative stockholders' equity of -$94.8K, indicating technical insolvency. Revenue has collapsed 92.4% YoY to essentially zero, while the company burns negative operating cash flow and carries $176.1K in long-term debt with no capacity to service it. The company faces imminent liquidity crisis without immediate capital injection or debt restructuring.
Goldenwell Biotech reports no revenue and continues to post operating losses with negative shareholders' equity and inadequate interest coverage, pointing to elevated solvency and execution risk. While near-term liquidity is acceptable, fundamentals remain weak until recurring revenue is reestablished and operating cash flow turns sustainably positive.
Goldenwell Biotech, Inc.. Key Strengths (GWLL)
- Current ratio of 6.37x suggests short-term current asset coverage, though largely illusory given negative equity
- Cash position of $45.6K provides minimal runway for operational adjustments
- Gross profit of $62.5K indicates some residual revenue-generating capability, though inconsistent with $0 revenue reporting
- Strong current ratio supports near-term liquidity
- Modest cash burn with near break-even FCF
- Small absolute operating loss relative to company size
GWLL Stock Risks: Goldenwell Biotech, Inc.. Investment Risks
- Negative stockholders' equity of -$94.8K represents technical insolvency with liabilities exceeding assets by $94.8K
- Revenue collapse of 92.4% YoY to $0.00 indicates cessation of business operations or catastrophic market loss
- Negative operating cash flow of -$3.8K combined with $176.1K debt burden and inability to service debt (interest coverage -6.6x) creates acute default risk
- No insider buying activity and complete operational shutdown suggest abandonment or imminent bankruptcy
- Zero revenue indicates weak commercial traction
- Negative shareholders' equity raises going-concern risk
- Negative interest coverage suggests debt service strain
Key Metrics to Watch
- Stockholders equity trend - recovery to positive required for viability
- Revenue stabilization - any return to non-zero sales critical indicator
- Debt restructuring or refinancing announcements - survival depends on creditor accommodation
- Revenue run-rate and customer traction
- Operating cash flow
Goldenwell Biotech, Inc.. (GWLL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.37x current ratio provides a solid financial cushion.
GWLL Profit Margin, ROE & Profitability Analysis
GWLL vs Consumer Sector: How Goldenwell Biotech, Inc.. Compares
How Goldenwell Biotech, Inc.. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Goldenwell Biotech, Inc.. Stock Overvalued? GWLL Valuation Analysis 2026
Based on fundamental analysis, Goldenwell Biotech, Inc.. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Goldenwell Biotech, Inc.. Balance Sheet: GWLL Debt, Cash & Liquidity
GWLL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Goldenwell Biotech, Inc..'s revenue has grown significantly by 199% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
GWLL Revenue Growth, EPS Growth & YoY Performance
GWLL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$20.8K | N/A |
| Q2 2024 | $139 | -$20.8K | N/A |
| Q1 2024 | $158 | -$20.8K | N/A |
| Q3 2023 | $382 | -$4.6K | N/A |
| Q2 2023 | $276 | -$4.6K | N/A |
| Q1 2023 | $397 | -$4.6K | N/A |
| Q3 2022 | $11.1K | -$4.6K | N/A |
| Q2 2022 | $1.1K | -$17.8K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Goldenwell Biotech, Inc.. Dividends, Buybacks & Capital Allocation
GWLL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Goldenwell Biotech, Inc.. (CIK: 0001800373)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GWLL
What is the AI rating for GWLL?
Goldenwell Biotech, Inc.. (GWLL) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GWLL's key strengths?
Claude: Current ratio of 6.37x suggests short-term current asset coverage, though largely illusory given negative equity. Cash position of $45.6K provides minimal runway for operational adjustments. ChatGPT: Strong current ratio supports near-term liquidity. Modest cash burn with near break-even FCF.
What are the risks of investing in GWLL?
Claude: Negative stockholders' equity of -$94.8K represents technical insolvency with liabilities exceeding assets by $94.8K. Revenue collapse of 92.4% YoY to $0.00 indicates cessation of business operations or catastrophic market loss. ChatGPT: Zero revenue indicates weak commercial traction. Negative shareholders' equity raises going-concern risk.
What is GWLL's revenue and growth?
Goldenwell Biotech, Inc.. reported revenue of $0.0.
Does GWLL pay dividends?
Goldenwell Biotech, Inc.. does not currently pay dividends.
Where can I find GWLL SEC filings?
Official SEC filings for Goldenwell Biotech, Inc.. (CIK: 0001800373) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GWLL's EPS?
Goldenwell Biotech, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GWLL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Goldenwell Biotech, Inc.. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GWLL stock overvalued or undervalued?
Valuation metrics for GWLL: ROE of N/A (sector avg: 18%), net margin of N/A (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
What is GWLL's AI grade for 2026?
Our dual AI analysis gives Goldenwell Biotech, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GWLL's free cash flow?
Goldenwell Biotech, Inc..'s operating cash flow is $-3.8K, with capital expenditures of N/A.
How does GWLL compare to other Consumer stocks?
Vs Consumer sector averages: Net margin N/A (avg: 8%), ROE N/A (avg: 18%), current ratio 6.37 (avg: 1.5).